Mountain View, CA -  May 31, 2024 -  Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, will showcase its latest non-incisional glaucoma treatments at the 16th European Glaucoma Society (EGS) Congress in Dublin, Ireland, from June 1-4, 2024. Attendees are invited to explore Iridex's glaucoma laser solutions at Booth #55.

"We are pleased to take part in the EGS, where we will highlight our versatile laser platforms and advanced technologies, providing a continuum of care from early to end-stage glaucoma," said Steven J Koufos; Vice President, Global Marketing.

MicroPulse Transscleral Laser Therapy (TLT)
A versatile, non-incisional, and repeatable procedure for glaucoma treatment using the Iridex Cyclo G6® Laser System and MicroPulse P3® Delivery Device.

Iridex-hosted MicroPulse TLT Drylab Session

• Sunday, June 2, 2024, titled “Non-incisional Glaucoma Treatment – The Versatility of MicroPulse Transscleral Laser Therapy” in Liffey Room 2, 10:30am-12:00pm

Posters on Iridex-patented MicroPulse® Technology

• Comparison of one-year outcomes between combined micropulse transscleral diode cyclo-photocoagulation with phacoemulsification and combined Hydrus microstent with phacoemulsification
• Safety and efficacy of micropulse transscleral cyclophotocoagulation in eyes affected by advanced primary glaucoma
• Micropulse transscleral cyclophotocoagulation in the treatment of secondary ocular hypertension in the eyes with vitreous hemorrhage Continuous-wave Transscleral Cyclophotocoagulation (CW-TSCPC)

Continuous-wave Transscleral Cyclophotocoagulation (CW-TSCPC)
Performed with the Cyclo G6® using G-Probe® and G-Probe Illuminate® delivery devices, offering a cost- effective, safe, and effective non-incisional glaucoma care solution.

Dedicated symposium on Continuous-wave and MicroPulse laser

• Associacion Argentina de Glaucoma Symposium - Continuous Diode and Micropulse Laser: The practice, its scope and current result

MicroPulse® Laser Trabeculoplasty (MLT)
Supported by Iridex 532 nm, 577 nm, and 810 nm laser platforms, MLT is a reasonable first-line therapy to address concerns of patient compliance with medical therapy, reduce patient costs and avoid medication side effects.

• Stela Vujosevic, MD, PhD, FEBO; Head of Medical Retina Unit at the University Eye Clinic, MultiMedica in Milan, Italy, commented, “Since 2009, I have been researching, and clinically applying, Iridex’ MicroPulse technology for safe and efficacious treatment of retinal disorders. More recently, my colleagues and I investigated the changes in intraocular pressure, functional parameters, and multimodal imaging in patients with ocular hypertension after MicroPulse Laser Trabeculoplasty. We are excited to share our research at EGS.”

For more information, please contact your Iridex sales professional or Iridex customer service at 1.650.940.4700 or customerservice@iridex.com.

About Iridex In 2024, Iridex Corporation celebrates its 35th anniversary as a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven therapy for targeted sight- threatening eye conditions. Iridex’ products treat glaucoma, diabetic macular edema, and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit www.iridex.com.

Iridex Media Contact
Joan Stauffer
Director, Marketing & Clinical Communications
jstauffer@iridex.com